Literature DB >> 1373939

Relation between drug resistance and antigenicity among norakin-resistant mutants of influenza A (fowl plague) virus.

A I Klimov1, S G Markushin, S Prösch, V P Ginzburg, H Heider, A M Heider, C Schröeder, R G Webster.   

Abstract

Norakin-resistant (NR) mutants of fowl plague virus (A/FPV/Weybridge, H7N7) have 1 to 2 (in one instance 3) amino acid substitutions in different positions of the heavy (HA 1) and/or light (HA 2) subunits of the haemagglutinin (HA) molecule. Investigation of NR mutants using the haemagglutination inhibition test with monoclonal antibodies (MAb) to the HA of A/seal/Massachusetts/80 (H7N7) virus revealed that one of the mutants (NR 1) differs antigenically from the wild-type fowl plague virus: its haemagglutination was not inhibited by MAb 55/2 and 58/6. By contrast, MAb-resistant (escape) mutants, selected from the wild-type fowl plague virus under pressure from MAb 55/2 or 58/6, showed reduced drug sensitivity. These findings suggest a possibility of correlation between alteration of influenza virus antigenicity and change of its sensitivity to drugs whose target is the haemagglutinin. This potential effect should be taken into account when antiviral substances directed to surface influenza virus antigens are being developed for use as antiviral drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373939     DOI: 10.1007/bf01314632

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  24 in total

1.  An analysis of the properties of monoclonal antibodies directed to epitopes on influenza virus hemagglutinin.

Authors:  L E Brown; J M Murray; D O White; D C Jackson
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

Review 2.  The structure and function of the hemagglutinin membrane glycoprotein of influenza virus.

Authors:  D C Wiley; J J Skehel
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

3.  Mutations in the hemagglutinin gene associated with influenza virus resistance to norakin.

Authors:  S Prösch; H Heider; C Schroeder; D H Krüger
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

4.  Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus.

Authors:  H Kida; L E Brown; R G Webster
Journal:  Virology       Date:  1982-10-15       Impact factor: 3.616

5.  Molecular basis of resistance of influenza A viruses to amantadine.

Authors:  A J Hay; M C Zambon; A J Wolstenholme; J J Skehel; M H Smith
Journal:  J Antimicrob Chemother       Date:  1986-10       Impact factor: 5.790

6.  Mapping mutations in influenza A virus resistant to norakin.

Authors:  S Prösch; H Heider; C Schroeder; A A Shilov; B V Sinitzyn; V M Blinov; D H Krüger; C Frömmel
Journal:  FEBS Lett       Date:  1990-07-02       Impact factor: 4.124

7.  The influence of Norakin on the reproduction of influenza A and B viruses.

Authors:  H Heider; S Markushin; C Schroeder; Y Ghendon
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

8.  Emergence and apparent transmission of rimantadine-resistant influenza A virus in families.

Authors:  F G Hayden; R B Belshe; R D Clover; A J Hay; M G Oakes; W Soo
Journal:  N Engl J Med       Date:  1989-12-21       Impact factor: 91.245

9.  Amantadine-resistance as a genetic marker for influenza viruses.

Authors:  G Appleyard
Journal:  J Gen Virol       Date:  1977-08       Impact factor: 3.891

10.  The molecular basis of the specific anti-influenza action of amantadine.

Authors:  A J Hay; A J Wolstenholme; J J Skehel; M H Smith
Journal:  EMBO J       Date:  1985-11       Impact factor: 11.598

View more
  1 in total

Review 1.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.